REG - Eco Animal Health Gp - EMA Positive Opinion Received for ECOVAXXIN® MS

ECO Animal HealthAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251110:nRSJ7800Ga&default-theme=true

RNS Number : 7800G  Eco Animal Health Group PLC  10 November 2025

10 November 2025

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

EMA Positive Opinion Received for ECOVAXXIN® MS poultry vaccine

Key milestone establishes roadmap for H2 2026 EU commercial launch

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that the Committee for Medicinal
Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has
adopted a Positive Opinion recommending the granting of EU marketing
authorisation for ECOVAXXIN® MS, a poultry vaccine
against Mycoplasma synoviae.

 

Based on the CVMP's Positive Opinion, the EMA is expected to issue a marketing
authorisation during the first quarter of 2026, and ECO Animal
Health anticipates making ECOVAXXIN® MS commercially available in the
European Union in the second half of 2026.

 

ECOVAXXIN® MS provides active immunisation of future layer and breeder
chickens from four weeks of age, helping to reduce air-sac and foot-pad
lesions caused by Mycoplasma synoviae infections. Air-sac and foot-pad
lesions cause economic loss, especially in laying hens, and the number of eggs
produced by affected layers can be reduced by 5-10%.

 

ECO Animal Health expects to submit additional geographic marketing
authorisation requests for ECOVAXXIN® MS, as well as submissions for further
vaccine products in its R&D pipeline, during the next 12 months.

 

David Hallas, Chief Executive Officer of ECO Animal Health, said: "We are
delighted to have received a Positive Opinion from the CVMP for ECOVAXXIN MS.
This significant milestone paves the way for a  mid-2026 EU launch for this
innovative vaccine product, in-line with our prior guidance.

 

"This marks an exciting time for the Company, with further submissions
expected over the next 12 months for additional products from our R&D
pipeline, underpinning ECO's next phase of growth. I'd like to thank our
R&D, regulatory, marketing, and technical teams for their hard work in
getting us to this point and look forward to updating the market on our
continued progress."

 

 

 

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZMGMNLDGKZM



            Copyright 2019 Regulatory News Service, all rights reserved